Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

401.00 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
65 66 Next >
Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?
There's more to consider with Vertex's valuation than one number. 
Via The Motley Fool
Stock-Split Watch: Is Vertex Pharmaceuticals Next?
It's on track to launch more blockbuster drugs. 
Via The Motley Fool
If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today
You can't go back in the past, but it's not too late to invest in this top stock. 
Via The Motley Fool
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
2 Healthcare Stocks That Could Help Set You Up for Life
These rock-solid businesses can add meaningful returns to a long-term portfolio. 
Via The Motley Fool
Could Vertex Pharmaceuticals Reach $500 in 2024?
Vertex shares have several catalysts on the horizon... 
Via The Motley Fool
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?
Its pain medicine isn't precisely what it hoped for, but it could still sell. 
Via The Motley Fool
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
 
Via Benzinga
3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector. 
Via InvestorPlace
Is Vertex Pharmaceuticals Stock a Buy Now?
The company just released its latest earnings report, and growth investors may be a little disappointed. 
Via The Motley Fool
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
These businesses are built to last. 
Via The Motley Fool
2 No-Brainer Healthcare Stocks to Buy Right Now
Companies in the healthcare industry tend to generate returns in a wide range of market environments. 
Via The Motley Fool
3 Stocks That Could Trounce the Market in 2024
These stocks appear to have what it takes to beat the market this year. 
Via The Motley Fool
3 Growth Stocks With More Potential Than Any Cryptocurrency
The stock market is full of opportunities for investors of all risk appetites and trading styles. 
Via The Motley Fool
This High-Flying Stock Just Got Some Bad News: Should You Sell?
It's just a minor setback for this leading biotech. 
Via The Motley Fool
Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat
The company also topped fourth-quarter expectations. 
Via Investor's Business Daily
3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List
These strong buy healthcare stocks are among analysts' favorite picks, and their strong market position tells us why. 
Via InvestorPlace
Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review
The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Vertex's Next-Generation Cystic Fibrosis Program Shows Efficacy With Reduced Burden, Provides Growth Opportunity: Goldman Sachs
Vertex Pharmaceuticals' cystic fibrosis treatment with vanza triple therapy. SKYLINE trials show non-inferiority to Trikafta, emphasizing once-daily dosing benefits. 
Via Benzinga
Vertex Pharmaceuticals' Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric Patients
Vertex Pharmaceuticals' vanza triple program for cystic fibrosis, with superior results in lung function, sweat chloride reduction, and safety. 
Via Benzinga
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest
Its foray into developing analgesics seems to be going swimmingly. 
Via The Motley Fool
Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024
Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements. 
Via InvestorPlace
Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript
VRTX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday?
Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for... 
Via Benzinga
Topics Economy
Vertex Pharmaceuticals Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 5, 2024. 
Via Benzinga
Will Jerome Powell Spoil Wall Street's Party? US Stock Futures Slip As Fed Chief Maintains Hawkish Tone Ahead Of More Earnings
As the market pushes higher despite the Federal Reserve's non-committal stance, traders fear a potential drawdown. 
Via Benzinga
Topics Economy
Earnings Scheduled For February 5, 2024
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is estimated to report quarterly earnings at $0.26 per share on revenue of $43.92 million. 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.